vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Palomar Holdings, Inc. (PLMR). Click either name above to swap in a different company.
Palomar Holdings, Inc. is the larger business by last-quarter revenue ($253.4M vs $196.0M, roughly 1.3× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 62.7%). Palomar Holdings, Inc. produced more free cash flow last quarter ($409.0M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 46.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Palomar Holdings, Inc. is a specialty insurance holding company that primarily provides property insurance products for catastrophe-exposed residential and commercial assets. It mainly operates across the United States, focusing on core segments including earthquake, flood, and windstorm coverage to meet high-risk property protection demands of customers.
AXSM vs PLMR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $253.4M |
| Net Profit | $-28.6M | — |
| Gross Margin | — | — |
| Operating Margin | -13.8% | 28.7% |
| Net Margin | -14.6% | — |
| Revenue YoY | 65.0% | 62.7% |
| Net Profit YoY | 61.9% | — |
| EPS (diluted) | $-0.55 | $2.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $253.4M | ||
| Q3 25 | $171.0M | $244.7M | ||
| Q2 25 | $150.0M | $203.3M | ||
| Q1 25 | $121.5M | $174.6M | ||
| Q4 24 | $118.8M | $155.8M | ||
| Q3 24 | $104.8M | $148.5M | ||
| Q2 24 | $87.2M | $131.1M | ||
| Q1 24 | $75.0M | $118.5M |
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $51.5M | ||
| Q2 25 | $-48.0M | $46.5M | ||
| Q1 25 | $-59.4M | $42.9M | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $30.5M | ||
| Q2 24 | $-79.3M | $25.7M | ||
| Q1 24 | $-68.4M | $26.4M |
| Q4 25 | -13.8% | 28.7% | ||
| Q3 25 | -27.0% | 27.4% | ||
| Q2 25 | -24.5% | 29.5% | ||
| Q1 25 | -46.9% | 30.8% | ||
| Q4 24 | -61.1% | 28.9% | ||
| Q3 24 | -59.8% | 25.9% | ||
| Q2 24 | -89.5% | 25.5% | ||
| Q1 24 | -89.7% | 29.0% |
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | 21.0% | ||
| Q2 25 | -32.0% | 22.9% | ||
| Q1 25 | -48.9% | 24.6% | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | 20.5% | ||
| Q2 24 | -91.0% | 19.6% | ||
| Q1 24 | -91.1% | 22.3% |
| Q4 25 | $-0.55 | $2.05 | ||
| Q3 25 | $-0.94 | $1.87 | ||
| Q2 25 | $-0.97 | $1.68 | ||
| Q1 25 | $-1.22 | $1.57 | ||
| Q4 24 | $-1.54 | $1.29 | ||
| Q3 24 | $-1.34 | $1.15 | ||
| Q2 24 | $-1.67 | $1.00 | ||
| Q1 24 | $-1.44 | $1.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $106.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $942.7M |
| Total Assets | $689.8M | $3.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $106.9M | ||
| Q3 25 | $325.3M | $111.7M | ||
| Q2 25 | $303.0M | $81.3M | ||
| Q1 25 | $300.9M | $119.3M | ||
| Q4 24 | $315.4M | $80.4M | ||
| Q3 24 | $327.3M | $86.5M | ||
| Q2 24 | $315.7M | $47.8M | ||
| Q1 24 | $331.4M | $61.4M |
| Q4 25 | $88.3M | $942.7M | ||
| Q3 25 | $73.7M | $878.1M | ||
| Q2 25 | $73.1M | $847.2M | ||
| Q1 25 | $53.2M | $790.4M | ||
| Q4 24 | $57.0M | $729.0M | ||
| Q3 24 | $92.9M | $703.3M | ||
| Q2 24 | $102.9M | $532.6M | ||
| Q1 24 | $144.0M | $501.7M |
| Q4 25 | $689.8M | $3.1B | ||
| Q3 25 | $669.3M | $2.9B | ||
| Q2 25 | $639.8M | $2.8B | ||
| Q1 25 | $596.7M | $2.4B | ||
| Q4 24 | $568.5M | $2.3B | ||
| Q3 24 | $561.5M | $2.3B | ||
| Q2 24 | $548.2M | $2.0B | ||
| Q1 24 | $545.7M | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $409.1M |
| Free Cash FlowOCF − Capex | $-18.7M | $409.0M |
| FCF MarginFCF / Revenue | -9.6% | 161.4% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $700.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $409.1M | ||
| Q3 25 | $1.0M | $83.6M | ||
| Q2 25 | $-32.4M | $120.9M | ||
| Q1 25 | $-43.4M | $87.2M | ||
| Q4 24 | $-26.2M | $261.2M | ||
| Q3 24 | $-18.6M | $100.3M | ||
| Q2 24 | $-30.1M | $55.1M | ||
| Q1 24 | $-53.5M | $33.1M |
| Q4 25 | $-18.7M | $409.0M | ||
| Q3 25 | $988.0K | $83.6M | ||
| Q2 25 | $-32.4M | $120.8M | ||
| Q1 25 | $-43.7M | $87.1M | ||
| Q4 24 | $-26.2M | $260.9M | ||
| Q3 24 | $-18.7M | $100.1M | ||
| Q2 24 | $-30.2M | — | ||
| Q1 24 | $-53.6M | — |
| Q4 25 | -9.6% | 161.4% | ||
| Q3 25 | 0.6% | 34.2% | ||
| Q2 25 | -21.6% | 59.4% | ||
| Q1 25 | -36.0% | 49.9% | ||
| Q4 24 | -22.1% | 167.5% | ||
| Q3 24 | -17.9% | 67.4% | ||
| Q2 24 | -34.6% | — | ||
| Q1 24 | -71.4% | — |
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.3% | 0.0% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | 0.1% | 0.0% | ||
| Q1 24 | 0.1% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.63× | ||
| Q2 25 | — | 2.60× | ||
| Q1 25 | — | 2.03× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.29× | ||
| Q2 24 | — | 2.14× | ||
| Q1 24 | — | 1.26× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
